Half Year 2025 Grifols SA Earnings Call Transcript
Key Points
- Grifols SA (GIFLF) reported a strong start to 2025 with a robust set of results across all key business and financial metrics, continuing the momentum from the first quarter.
- The company achieved a year-over-year revenue increase of 7% on a reported basis and 10.1% like-for-like at constant currency, demonstrating strong business momentum.
- Adjusted EBITDA reached EUR876 million, up 12.7% on a reported basis and 20.1% like-for-like, indicating significant improvement in profitability.
- Grifols SA (GIFLF) reinstated its dividend payment, reflecting confidence in its value creation plan and commitment to shareholders.
- The company is making significant strides in innovation, with the upcoming launch of Fibrinogen in Europe and the USA, and progress in its pipeline execution, including the GIGA-564 oncology program and IG in dry eye disease.
- Foreign exchange volatility continues to present challenges, impacting revenues and EBITDA, although the overall effect on group profit and free cash flow is broadly neutral.
- There is pricing pressure in the Chinese Albumin market due to government efforts to reduce healthcare costs, which could affect future growth.
- The company faces uncertainties from the Inflation Reduction Act and potential geopolitical and economic headwinds, including tariffs and currency fluctuations.
- Despite strong performance, the company acknowledges the complex macroeconomic environment and persistent uncertainties that require vigilance and adaptability.
- The launch of new products, such as Fibrinogen in the US, will take time to establish a new standard of care, indicating a gradual ramp-up in sales.
Hello everyone. My name is Danny Segarra, and I serve as the Head of Investor Relations and Sustainability and Vice President at Grifols. Welcome to our review of the company's business results for the first half of 2025.
Today I'm joined by Grifols's Chief Executive Officer, Nacho Abia; Chief Financial Officer, Rahul Srinivasan; and the President of Biopharma, Roland Wandeler.
A few logistics before we get into the details. Today's call will last about an hour, including a Q&A session. As a reminder, this call is being recorded. You can find additional materials, including today's presentation in the Investor Relations section of the Grifols website at grifols.com. The transcript and a replay of the webcast will also be available on the Investor Relations website within 24 hours.
Turning to slide 2, please note that this presentation includes forward-looking statements regarding, among other things, the company's future operating and financial performance, market position and
| Access to All Earning Calls and Stock Analysis | |
| 30-Year Financial on one screen | |
| All-in-one Stock Screener with unlimited filters | |
| Customizable Stock Dashboard | |
| Real Time Insider Trading Transactions | |
| 8,000+ Institutional investors’ 13F holdings | |
| Powerful Excel Add-in and Google sheets Add-on | |
| All data downloadable | |
| Quick customer support | |
| And much more... |
Trustpilot
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
